ゲノム編集技術を用いて改変されたヒト細胞加工製品の非臨床安全性評価

真木一茂 · Institutional Repositories DataBase (IRDB)

Gene-edited cellular therapy products (ex vivo gene-edited products) are categorized as cellular and tissue-based products in Japan. However, PMDA requests their safety assessment according to the guidelines for not only cellular and tissue-based products, but also gene therapy products. In this presentation, I will outline the basic concepts related to the preclinical safety assessment of the cellular and tissue-based products and the gene therapy products, and then introduce the general principles for nonclinical safety evaluation of ex vivo gene-edited products, focusing on safety concerns specific to this technology.

Cited by 0 works.

Authors